Plasma Fractionation Market

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) - Global Forecast to 2025

Report Code: BT 3042 Sep, 2020, by marketsandmarkets.com

[278 Pages Report] The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.

Attractive Opportunities in the Plasma fractionation Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the plasma fractionation market

COVID-19 is an infectious disease caused by the recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic in March 2020. A number of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments that target the infection caused by the novel coronavirus. Although, no specific drugs have been approved yet for its treatment, based on the positive findings of a number of clinical trials, convalescent plasma (CP) therapy is expected to increase the survival rate of COVID-19 patients. Hence, federal agencies of various countries such as the US and India are taking initiatives to offer this therapy to patients as quickly as possible, while at the same time conducting the clinical trials to find out the safety and effectiveness of the therapy. For instance,

  • In May 2020, the National Agency for Medicines and Health Products Safety (ANSM) in France announced immune plasma therapy could be used to treat critically ill patients.
  • In April 2020, the Indian Council for Medical Research (ICMR) approved Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST, India) to develop a protocol for convalescent plasma therapy trials to treat severely ill COVID-19 patients.
  • In April 2020, the European Commission recommended that transfusion of COVID-19 convalescent plasma, as an immediately available experimental therapy with low risk, should be considered as an urgent priority and its outcome monitored.

Global Plasma fractionation Market Dynamics

DRIVER: Growing use of immunoglobulins in various therapeutic areas

Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. The most common use of immunoglobulin therapy is for the treatment of primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being considered for a range of neurological diseases, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome.

In the last decade, the diagnosis rate of various immunological diseases has increased due to technological advancements. In addition, growing genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins due to the increased number of diagnosed patients.

RESTRAINT:  Emergence of recombinant alternatives

In the last few years, many recombinant alternatives have been developed for various plasma-derived products, such as factor VIII, factor IX, von Willebrand factor, fibrinogen concentrates, antithrombins, and protease inhibitors. In developed countries, recombinant factors VIII and IX are increasingly being used as an alternative to plasma-derived factors VIII and IX in bleeding disorders. These recombinant products are used prophylactically and are less immunogenic than plasma-derived products. In addition to these, there are a few more longer-acting replacement factors in the development pipeline. These products would provide significant benefits, such as less-frequent administration and greater effectiveness in prophylactic use. The increasing use of recombinant factors and their increased use in prophylactic therapies is thus a major factor limiting the adoption of plasma products.

OPPORTUNITY: Rising prevalence of bleeding disorders

Hemophilia or hematology disorders form one of the major application areas of plasma fractionation products. Hemophilia is a hereditary bleeding disorder characterized by impaired blood coagulation due to deficiencies in the production or function of coagulation factor VIII. According to the World Federation of Hemophilia, the number of hemophilia patients worldwide was 167,110 in 2011, which increased by 25.9% to 210,454 in 2018. Only 30% of patients are actually diagnosed with hemophilia, and 25% of them receive treatment. The rest of the people with hemophilia remain undiagnosed, and nearly 75% of patients receive inadequate treatment or no treatment at all.

The immunoglobins segment will witness the highest growth during the forecast period.

Based on product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products. The immunoglobulins segment accounted for the largest share of the plasma fractionation market in 2019. This segment is also expected to register the highest CAGR during the forecast period. The large share of this segment is attributed to the rising adoption of SCIg and the increasing on- and off-label use of immunoglobulins for various indications. 

The neurology segment dominated the plasma fractionation market in 2019. 

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the neurology segment accounted for the largest share of the global plasma fractionation market. The large share of this segment can primarily be attributed to the response of IVIg in a shorter period than steroids or oral immunosuppressants and its effectiveness in a number of disorders of the peripheral and central nervous systems.

Plasma Fractionation Market By Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for plasma fractionation in 2019.

Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing use of immunoglobulins in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD.

Key Market Players

Key players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), and BPL (UK), Sanquin (Netherlands),

Scope of the report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Product, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Sanquin (Netherlands), China Biologic Products (UK), Bio Products Laboratory (UK), Japan Blood Products Organization (Japan), Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Emergent BioSolutions (US), Intas Biopharmaceuticals (India), Bharat Serums and Vaccines Limited (India), SK Plasma (Republic of Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Turkey)

This report categorizes the plasma fractionation market into the following segments and subsegments:

By Product

  • Immunoglobulins
  • Intravenous Immunoglobulins
  • Subcutaneous Immunoglobulins
  • Other Immunoglobulins
  • Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • Von Willebrand Factor
  • Prothrombin Complex Concentrate
  • Fibrinogen Concentrates
  • Factor XIII
  • Albumin
  • Protease Inhibitors
  • Other Products

By Application

  • Neurology
  • Immunology
  • Hematology
  • Critical care
  • Pulmonology
  • Hemato-oncology
  • Rheumatology
  • Other Applications

By End User

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Academic Institutes 

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • RoE
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Vietnam
    • Indonesia
    • Malaysia
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • Egypt
    • UAE
  • Rest of Middle East and Africa 

Recent Developments

  • In April 2020, Grifols (Spain) launched 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]) in the plasma fractionation market.
  • In April 2020, Biotest (Germany), BPL (UK), LFB (France), and Octapharma (Switzerland) joined an alliance formed by CSL Behring (Australia) and Takeda Pharmaceutical Company Limited (Japan) to develop a potential plasma-derived therapy for treating COVID-19.
  • In April 2020, Octapharma (Switzerland) formed an alliance with CSL (Australia), Takeda (Japan), BPL (UK), Biotest (Germany), and LFB (France) to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19. 

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. -33)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 SCOPE OF THE STUDY
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
        TABLE 1 STANDARD CURRENCY CONVERSION RATE
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH APPROACH
        FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY SOURCES
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY SOURCES
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                            FIGURE 2 SUPPLY SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
        FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
        FIGURE 4 MARKET SIZE ESTIMATION: PLASMA FRACTIONATION MARKET
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
        FIGURE 6 ASSUMPTIONS FOR THE STUDY
        FIGURE 7 LIMITATIONS OF THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 47)
  FIGURE 8 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
  FIGURE 9 PLASMA FRACTIONATION MARKET, BY APPLICATION,2020 VS. 2025 (USD MILLION)
  FIGURE 10 PLASMA FRACTIONATION MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
  FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET

4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 PLASMA FRACTIONATION MARKET OVERVIEW
        FIGURE 12 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
    4.2 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT & COUNTRY (2019)
        FIGURE 13 IMMUNOGLOBULINS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 2019
    4.3 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
        FIGURE 14 CHINA TO REGISTER THE HIGHEST CAGR IN THE PLASMA FRACTIONATION MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        TABLE 2 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
                            TABLE 3 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
                            TABLE 4 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION (AS OF JULY 2020)
                            TABLE 5 NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN THE UK
                    5.2.1.2 Rising geriatric population
                            TABLE 6 GERIATRIC POPULATION, BY REGION, 2000?2050
                    5.2.1.3 Growing prevalence of respiratory diseases and AATD
                            FIGURE 15 GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High cost and limited reimbursement
                    5.2.2.2 Emergence of recombinant alternatives
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Increased risk of pandemics and communicable diseases
                    5.2.3.2 Rising prevalence of bleeding disorders
                            FIGURE 16 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012-2018
                            TABLE 7 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2018
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Stringent government regulations

6 INDUSTRY INSIGHTS (Page No. - 61)
    6.1 INTRODUCTION
    6.2 KEY INDUSTRY TRENDS
           6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES
                 TABLE 8 FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS
           6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS
           6.2.3 RISING ADOPTION OF SCIG
           6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
           6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA
                 FIGURE 17 PLASMA FRACTIONATION MARKET IN CHINA VS. THE US, 2018-2025
                 TABLE 9 CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2019
                 TABLE 10 MAJOR LOCAL PLAYERS IN CHINA
           6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS
                 TABLE 11 REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS
    6.3 PORTER'S FIVE FORCES
        FIGURE 18 PORTER'S FIVE FORCES ANALYSIS
           6.3.1 THREAT OF NEW ENTRANTS
           6.3.2 THREAT OF SUBSTITUTES
           6.3.3 BARGAINING POWER OF SUPPLIERS
           6.3.4 BARGAINING POWER OF BUYERS
           6.3.5 INTENSITY OF COMPETITIVE RIVALRY
    6.4 VENDOR BENCHMARKING
           6.4.1 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET
           6.4.2 NUMBER OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER
           6.4.3 BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN
    6.5 PRICING ANALYSIS
        TABLE 12 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY PLAYER (2019)
        TABLE 13 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION (2019)
    6.6 PLASMA COLLECTION
        FIGURE 19 SOURCE PLASMA COLLECTION IN THE US, 2008-2019
        FIGURE 20 PLASMA COLLECTION CENTERS IN THE US, 2005-2018
        FIGURE 21 EUROPE: PLASMA COLLECTION, 2007-2019
        TABLE 14 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2019
        TABLE 15 PLASMA COLLECTION, BY REGION, 2018-2025 (MILLION LITER)
        TABLE 16 NORTH AMERICA: PLASMA COLLECTION, BY COUNTRY, 2018-2025 (MILLION LITER)
    6.7 IMPACT OF COVID-19 ON THE PLASMA FRACTIONATION MARKET
        TABLE 17 COVID-19- CLINICAL TRIALS WITH KEY FINDINGS
        TABLE 18 CLINICAL TRIALS OF CONVALESCENT PLASMA EXPECTED TO COMPLETE THIS YEAR
 
7 PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. - 80)
    7.1 INTRODUCTION
        TABLE 19 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    7.2 IMMUNOGLOBULINS
        TABLE 20 IVIG VS. SCIG THERAPY
        TABLE 21 IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
        TABLE 22 IMMUNOGLOBULINS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
           7.2.1 INTRAVENOUS IMMUNOGLOBULINS
                     7.2.1.1 IVIg holds the largest share of the immunoglobulins market
                             TABLE 23 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                             TABLE 24 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 25 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION, 2018-2025 (METRIC TONS)
           7.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
                     7.2.2.1 Benefit of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market
                             TABLE 26 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                             TABLE 27 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 28 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION, 2018-2025 (METRIC TONS)
           7.2.3 OTHER IMMUNOGLOBULINS
                             TABLE 29 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
                             TABLE 30 OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 31 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2018-2025 (MILLION INTERNATIONAL UNITS)
    7.3 COAGULATION FACTOR CONCENTRATES
        TABLE 32 COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
        TABLE 33 COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
           7.3.1 FACTOR VIII
                     7.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market
                             TABLE 34 FACTOR VIII OFFERED BY KEY MARKET PLAYERS
                             TABLE 35 FACTOR VIII MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 36 FACTOR VIII MARKET, BY REGION, 2018-2025 (MILLION INTERNATIONAL UNITS)
           7.3.2 FACTOR IX
                     7.3.2.1 Rising number of hemophilic patients is expected to drive the growth of this market
                             TABLE 37 FACTOR IX OFFERED BY KEY MARKET PLAYERS
                             TABLE 38 FACTOR IX MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 39 FACTOR IX MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT)
           7.3.3 VON WILLEBRAND FACTOR
                     7.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of von Willebrand disease and hemophilia
                             TABLE 40 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
                             TABLE 41 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 42 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT)
           7.3.4 PROTHROMBIN COMPLEX CONCENTRATES
                     7.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment
                             TABLE 43 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
                             TABLE 44 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 45 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT)
           7.3.5 FIBRINOGEN CONCENTRATES
                     7.3.5.1 Safety profile, accuracy, and speed of administration are supporting the growth of the fibrinogen concentrates market
                             TABLE 46 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
                             TABLE 47 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 48 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT) 110
           7.3.6 FACTOR XIII
                     7.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for factor XIII
                             TABLE 49 FACTOR XIII OFFERED BY KEY MARKET PLAYERS
                             TABLE 50 FACTOR XIII MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                             TABLE 51 FACTOR XIII MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT)
    7.4 ALBUMINS
           7.4.1 RISING DEMAND FOR ALBUMIN AS AN ANTIOXIDANT TO DRIVE MARKET GROWTH
                 TABLE 52 ALBUMINS OFFERED BY KEY MARKET PLAYERS
                 TABLE 53 ALBUMINS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                 TABLE 54 ALBUMINS MARKET, BY REGION, 2018-2025 (MILLION INTERNATIONAL UNIT)
    7.5 PROTEASE INHIBITORS
           7.5.1 RISING PREVALENCE OF COPD WILL DRIVE THE DEMAND FOR PROTEASE INHIBITORS
                 TABLE 55 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
                 TABLE 56 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
                 TABLE 57 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2018-2025 (MILLION INTERNATIONAL UNIT)
    7.6 OTHER PRODUCTS
        TABLE 58 OTHER PRODUCTS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

8 PLASMA FRACTIONATION MARKET, BY APPLICATION (Page No. - 120)
    8.1 INTRODUCTION
        TABLE 59 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    8.2 NEUROLOGY
           8.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
                 TABLE 60 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
                 TABLE 61 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
                 TABLE 62 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.3 IMMUNOLOGY
           8.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET
                 TABLE 63 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
                 TABLE 64 DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASE
                 TABLE 65 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
                 TABLE 66 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
                 TABLE 67 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.4 HEMATOLOGY
           8.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
                 TABLE 68 NUMBER OF HEMOPHILIA PATIENTS (2012-2018)
                 TABLE 69 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
                 TABLE 70 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.5 CRITICAL CARE
           8.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
                 TABLE 71 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
                 TABLE 72 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2018-2025 (USD MILLION)
    8.6 PULMONOLOGY
           8.6.1 RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
                 TABLE 73 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
                 TABLE 74 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.7 HEMATO-ONCOLOGY
           8.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS
                 TABLE 75 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA, BY REGION, 2012?2018
                 TABLE 76 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
                 TABLE 77 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.8 RHEUMATOLOGY
           8.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
                 TABLE 78 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    8.9 OTHER APPLICATIONS
        TABLE 79 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
        TABLE 80 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)

9 PLASMA FRACTIONATION MARKET, BY END USER (Page No. - 138)
    9.1 INTRODUCTION
        TABLE 81 PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
    9.2 HOSPITALS & CLINICS
           9.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS-KEY FACTORS DRIVING GROWTH
                 TABLE 82 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2018-2025 (USD MILLION)
    9.3 CLINICAL RESEARCH LABORATORIES
           9.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET GROWTH
                 TABLE 83 CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN, BY REGION (2017)
                 TABLE 84 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2018-2025 (USD MILLION)
    9.4 ACADEMIC INSTITUTES
           9.4.1 GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES
                 TABLE 85 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2018-2025 (USD MILLION)

10 PLASMA FRACTIONATION MARKET, BY REGION (Page No. - 144)
     10.1 INTRODUCTION
          TABLE 86 PLASMA FRACTIONATION MARKET, BY REGION, 2018-2025 (USD MILLION)
     10.2 NORTH AMERICA
          FIGURE 22 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
          TABLE 87 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 88 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
          TABLE 89 NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 90 NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 91 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
          TABLE 92 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.2.1 US
                      10.2.1.1 The US dominates the global plasma fractionation market
                               TABLE 93 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 94 US: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 95 US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 96 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 97 US: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.2.2 CANADA
                      10.2.2.1 Canada is among the world's highest per capita users of IVIg
                               TABLE 98 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 99 CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 100 CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 101 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 102 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
     10.3 EUROPE
          TABLE 103 PLASMA FRACTIONATION PLANTS IN EUROPE (2017)
          TABLE 104 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 105 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
          TABLE 106 EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 107 EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 108 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
          TABLE 109 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.1 GERMANY
                      10.3.1.1 Germany has the highest plasma fractionation capacity in Europe
                               TABLE 110 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 111 GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 112 GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 113 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 114 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.2 FRANCE
                      10.3.2.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France
                               TABLE 115 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012-2018
                               TABLE 116 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 117 FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 118 FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 119 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 120 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.3 ITALY
                      10.3.3.1 Growth in the country's geriatric population to drive the market for plasma fractionation
                               TABLE 121 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E)
                               TABLE 122 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 123 ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 124 ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 125 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 126 ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.4 SPAIN
                      10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth
                               TABLE 127 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 128 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 129 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 130 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 131 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.5 UK
                      10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK
                               TABLE 132 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN THE UK, 2012-2018
                               TABLE 133 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 134 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 135 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 136 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 137 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.3.6 REST OF EUROPE
                   TABLE 138 ROE: NUMBER OF HEMOPHILIA PATIENTS, BY COUNTRY, 2012-2018
                   TABLE 139 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                   TABLE 140 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 141 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 142 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                   TABLE 143 ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
     10.4 ASIA PACIFIC
          FIGURE 23 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
          TABLE 144 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 145 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
          TABLE 146 ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 147 ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 148 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
          TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2019-2025 (USD MILLION)
            10.4.1 CHINA
                      10.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market growth in China
                               TABLE 150 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 151 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 152 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 153 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 154 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.2 JAPAN
                      10.4.2.1 Rising prevalence of neurological disorders and hematological diseases will support market growth in the country
                               TABLE 155 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS.2018 (IN IU/TOTAL POPULATION
                               TABLE 156 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2018
                               TABLE 157 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 158 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 159 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 160 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 161 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.3 AUSTRALIA
                      10.4.3.1 Growing demand for plasma products for the treatment of chronic disease to drive market growth
                               TABLE 162 TOTAL IG (GRAMS  USED IN AUSTRALIA, 2008/09-2017/18
                               TABLE 163 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008-2018 (USD MILLION)
                               FIGURE 24 FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008-2018 (USD MILLION)
                               TABLE 164 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017
                               TABLE 165 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 166 AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 167 AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 168 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 169 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.4 INDIA
                      10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth
                               TABLE 170 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012-2018
                               TABLE 171 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 172 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 173 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 174 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 175 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.5 VIETNAM
                      10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth
                               FIGURE 25 MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM, 2014-2018 (IU/POPULATION
                               FIGURE 26 PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS IN VIETNAM, 2014-2018
                               TABLE 176 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 177 VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 178 VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 179 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 180 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.6 INDONESIA
                      10.4.6.1 Growing government initiatives to drive market growth
                               TABLE 181 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 182 INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 183 INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 184 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 185 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.7 MALAYSIA
                      10.4.7.1 Increasing prevalence of bleeding disorders will support the plasma fractionation market in Malaysia
                               TABLE 186 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 187 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 188 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 189 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 190 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.4.8 REST OF ASIA PACIFIC
                   TABLE 191 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                   TABLE 192 REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 193 REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 194 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                   TABLE 195 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
     10.5 LATIN AMERICA
            10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES WILL DRIVE MARKET GROWTH IN LATIN AMERICA
                   TABLE 196 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                   TABLE 197 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 198 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 199 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                   TABLE 200 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
          TABLE 201 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, BY COUNTRY, 2012-2018
          TABLE 202 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION  IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012-2018)
          TABLE 203 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
          TABLE 204 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
          TABLE 205 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 206 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
          TABLE 207 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
          TABLE 208 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.6.1 TURKEY
                      10.6.1.1 Turkey dominates the plasma fractionation market in the Middle East and Africa
                               TABLE 209 TURKEY: DEMOGRAPHIC INDICATORS
                               TABLE 210 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 211 TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 212 TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 213 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 214 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.6.2 SAUDI ARABIA
                      10.6.2.1 Developments in healthcare infrastructure to support market growth
                               TABLE 215 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 216 SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 217 SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 218 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 219 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.6.3 EGYPT
                      10.6.3.1 Growing research on plasma and plasma derivatives will support market growth
                               TABLE 220 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 221 EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 222 EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 223 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 224 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.6.4 UAE
                      10.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market growth in the UAE
                               TABLE 225 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                               TABLE 226 UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 227 UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                               TABLE 228 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                               TABLE 229 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)
            10.6.5 REST OF THE MIDDLE EAST AND AFRICA
                   TABLE 230 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA, 2012?2018
                   TABLE 231 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
                   TABLE 232 ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 233 ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018-2025 (USD MILLION)
                   TABLE 234 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
                   TABLE 235 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2018-2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 215)
     11.1 OVERVIEW
     11.2 MARKET EVALUATION FRAMEWORK
          TABLE 236 GROWTH STRATEGY MATRIX: EXPANSIONS AND COLLABORATIONS ARE THE WIDELY ADOPTED GROWTH STRATEGIES BY MARKET PLAYERS 215
     11.3 COMPETITIVE SCENARIO AND TRENDS
          TABLE 237 PRODUCT LAUNCHES & APPROVALS, JANUARY 2017?JULY 2020
          TABLE 238 EXPANSIONS, JANUARY 2017?JULY 2020
          TABLE 239 ACQUISITIONS, JANUARY 2017?JULY 2020
          TABLE 240 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, JANUARY 2017?JULY 2020

12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 219)
     12.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
            12.1.1 MARKET SHARE ANALYSIS
                   FIGURE 27 PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
            12.1.2 MARKET SHARE ANALYSIS, BY PRODUCT, 2019
                      12.1.2.1 Immunoglobulins market, by key player
                                    12.1.2.1.1 IVIg market, by key player
                      12.1.2.2 Coagulation factors market, by key player
                                    12.1.2.2.1 Factor VIII market, by key player
                      12.1.2.3 Albumins market, by key player
            12.1.3 MARKET SHARE ANALYSIS, BY REGION, 2019
                      12.1.3.1 North America: Plasma fractionation market, by key player
                                    12.1.3.1.1 US: Plasma fractionation market, by key player
                   12.1.3.2 Europe: Plasma fractionation market, by key player
     12.2 COMPANY EVALUATION MATRIX
            12.2.1 STARS
            12.2.2 EMERGING LEADERS
            12.2.3 PERVASIVE
            12.2.4 EMERGING COMPANIES
                   FIGURE 28 COMPETITIVE LEADERSHIP MAPPING
     12.3 COMPANY PROFILES
(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
            12.3.1 CSL
                   FIGURE 29 CSL: COMPANY SNAPSHOT (2019)
            12.3.2 GRIFOLS
                   FIGURE 30 GRIFOLS: COMPANY SNAPSHOT (2019)
            12.3.3 SHIRE
                   FIGURE 31 TAKEDA PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
            12.3.4 OCTAPHARMA
                   FIGURE 32 OCTAPHARMA: COMPANY SNAPSHOT (2019)
            12.3.5 KEDRION
                   FIGURE 33 KEDRION: COMPANY SNAPSHOT (2019)
            12.3.6 LFB
                   FIGURE 34 LFB: COMPANY SNAPSHOT (2016)
            12.3.7 BIOTEST
                   FIGURE 35 BIOTEST: COMPANY SNAPSHOT (2019)
            12.3.8 SANQUIN
                   FIGURE 36 SANQUIN: COMPANY SNAPSHOT (2018)
            12.3.9 CHINA BIOLOGIC PRODUCTS
                   FIGURE 37 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2019)
            12.3.10 BIO PRODUCTS LABORATORY
            12.3.11 JAPAN BLOOD PRODUCTS ORGANIZATION
                    FIGURE 38 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2019)
            12.3.12 GC PHARMA
                    FIGURE 39 GC PHARMA: COMPANY SNAPSHOT (2019)
            12.3.13 SHANGHAI RAAS BLOOD PRODUCTS
            12.3.14 EMERGENT BIOSOLUTIONS
                    FIGURE 40 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2019)
            12.3.15 INTAS BIOPHARMACEUTICALS
                    FIGURE 41 INTAS BIOPHARMACEUTICALS: COMPANY SNAPSHOT (2019)
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies
            12.3.16 OTHER COMPANIES
                      12.3.16.1 Bharat Serums and Vaccines Limited
                      12.3.16.2 SK Plasma
                      12.3.16.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
                      12.3.16.4 Kabafusion
                      12.3.16.5 Centurion Pharma
 
13 APPENDIX (Page No. - 271)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the plasma fractionation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research;

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. The secondary sources used for this study include the International Plasma Fractionation Association (IPFA), Plasma Protein Therapeutics Association (PPTA), International Plasma Products Industry Association (IPPIA), European Association of the Plasma Products Industry (EAPPI), World Health Organization (WHO), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. 

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Plasma Fractionation Market Size

To know about the assumptions considered for the study, download the pdf brochure

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2019, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the plasma fractionation business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global plasma fractionation market based on the product, application, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall plasma fractionation market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the plasma fractionation market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
COVID-19

Get in-depth analysis of the COVID-19 impact on the Plasma Fractionation Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Plasma Fractionation Market

Request For Special Pricing
Report Code
BT 3042
Published ON
Sep, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Plasma Fractionation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home